Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Renvela, Renagel
Sevelamer is a phosphate binder used to control serum phosphorus levels in patients with chronic kidney disease (CKD) who are on dialysis. It is a non-absorbed polymer that binds phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream. It is available in both hydrochloride and carbonate forms, with the latter also offering some acid-neutralizing capacity. Sevelamer does not contain calcium or metal and is therefore a preferred option for patients at risk of hypercalcemia or metal overload.
For controlling serum phosphorus levels in patients with chronic kidney disease on dialysis.
Outcome:
Reduced ciprofloxacin absorption
Mechanism:
Binding in the GI tract
Outcome:
May reduce the absorption of some antihypertensives
Mechanism:
Unknown
Outcome:
May slightly reduce the effectiveness of sevelamer
Mechanism:
Altered pH in the GI tract
Most likely new formulation: extended-release sevelamer (Year: 2025, 75% confidence)
Based on current usage trends and clinical trial data, sevelamer is expected to maintain its market share in the phosphate binder market with a 90% likelihood of continued FDA approval.
Phosphate Binder
Cross-linked poly(allylamine hydrochloride)